Targeted therapy combination improves survival in patients with advanced bowel cancer

New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC Phase III trial have shown that triple therapy targeting BRAF mutations in progressive metastatic colorectal tumours significantly improved overall survival and objective response compared to standard care.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/targeted-therapy-combination-improves-survival-in-patients-with-advanced-bowel-cancer